Open Government Portal
Found 10 records similar to HIV and AIDS: For health professionals
Find information, tools and facts about symptoms, risks and how to prevent, treat and manage HIV and AIDS.
HIV diagnosis rates remained stable over the last decade, with some minor fluctuations.
The number of persons who are infected with HIV and not yet tested (i.e. are not even aware themselves that they have HIV) is impossible to know precisely. This number is estimated using statistical models and methods with data from a variety of sources.
This evaluation covered the activities of the Federal Initiative (FI) to Address HIV/AIDS in Canada for the period of 2013-14 to 2017-18. FI represents an annual investment ranging from $70 to $78 million. The evaluation was undertaken in fulfillment of the requirements of the Financial Administration Act and the Treasury Board of Canada's Policy on Results (2016).
In 2016, an estimated 63,110 people were living with HIV.
Age-sex Specific Incidence Rates for HIV for Alberta expressed as per 100,000 population.
A series of health-related data sets from various quantitative public opinion research studies.
The Cancer in Young People in Canada (CYP-C) program maintains a national childhood cancer
surveillance and research database that is available to researchers seeking to improve cancer diagnosis,
treatment, and outcomes.
The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG.